Works matching IS 14642662 AND DT 2015 AND VI 16 AND IP 2
Results: 8
Autoantibodies binding to ubiquitin-fold modifier-conjugating enzyme 1 ( Ufc1) and pleckstrin homology domain containing, family G (with Rho Gef domain) member 2 ( Plekhg2) are associated with mycobacterial infections.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 114, doi. 10.1111/hiv.12194
- By:
- Publication type:
- Article
Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 76, doi. 10.1111/hiv.12173
- By:
- Publication type:
- Article
Factors responsible for incomplete linkage to care after HIV diagnosis: preliminary results from the Test and Keep in Care ( TAK) project.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 88, doi. 10.1111/hiv.12175
- By:
- Publication type:
- Article
Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief ( PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 95, doi. 10.1111/hiv.12177
- By:
- Publication type:
- Article
Prevalence and correlates of obstructive sleep apnoea among patients with and without HIV infection.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 105, doi. 10.1111/hiv.12182
- By:
- Publication type:
- Article
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 132, doi. 10.1111/hiv.12183
- By:
- Publication type:
- Article
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
- Published in:
- HIV Medicine, 2015, v. 16, n. 2, p. 122, doi. 10.1111/hiv.12186
- By:
- Publication type:
- Article
Is HIV post-exposure prophylaxis required following occupational exposure to a source patient who is virologically suppressed on antiretroviral therapy?
- Published in:
- 2015
- By:
- Publication type:
- Editorial